Fipravirimat
Appearance
Clinical data | |
---|---|
Other names | GSK3640254 |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Fipravirimat is an experimental drug for the treatment of HIV/AIDS. It belongs to a class of drugs known as maturation inhibitors.[1][2]
Fipravirimat was being developed by ViiV Healthcare, but development was stopped in 2023.[3]
See also
References
- ^ "Fipravirimat". PubChem. U.S. National Library of Medicine.
- PMID 34780263.
- ^ Waldron, James (2023-04-26). "GSK drops one of 2 maturation inhibitors in HIV pipeline". Retrieved 2023-09-18.